Skip to main content
. Author manuscript; available in PMC: 2020 Feb 19.
Published in final edited form as: Breast Cancer Res Treat. 2019 Sep 27;179(1):67–77. doi: 10.1007/s10549-019-05454-y

Figure 4. A clinically relevant dose of fulvestrant inhibited estrogen dependent tumor growth.

Figure 4.

A) Ovariectomized Nu:J mice bearing HCC1428 breast cancer xenograft tumors were randomized to treatment with vehicle or fulvestrant (25 mg/kg sc qw). *As compared to the vehicle control, significant (p > 0.05) inhibition of tumor growth by fulvestrant was observed for multiple time points. B) ER levels present in tumors harvested from mice included in (A) were analyzed by western blotting of tissue extracts. A significant (p < 0.05) decrease in ER levels was observed for fulvestrant treatment. Primary western blot images are included in online resource Fig. 3C.